Clinical benefit from palliative chemotherapy in non-small-cell lung cancer extends to the elderly and those with poor prognostic factors
Open Access
- 1 July 1998
- journal article
- Published by Springer Nature in British Journal of Cancer
- Vol. 78 (1) , 28-33
- https://doi.org/10.1038/bjc.1998.437
Abstract
The intention of this study was to identify the pretreatment characteristics predicting for the survival, objective response and symptom relief in patients with non-resectable, non-small-cell lung cancer (NSCLC) managed in the Lung Unit at the Royal Marsden Hospital. This analysis included 290 patients with advanced NSCLC generally treated with a cisplatin-based chemotherapy regimen in one of a series of trials. Thirty-seven pretreatment variables, response and survival data were collected prospectively and analysed using univariate and multivariate methods. By multivariate analysis performance status, disease extent and pattern of metastases along with certain biochemical features were influential independent variables for survival, objective and symptom response. Older age was positively associated with objective response (P = 0.04). When the independent factors for symptom response were used to group patients into prognostic categories, 30-48% of patients with an adverse set of factors had symptom relief. Similarly using the relative risk of death to subgroup the patient population, 54% of patients at high risk of death (greater than 8.0), with a median survival of 2.5 months, had symptom relief. The data are consistent with other studies in identifying the pretreatment factors predicting for survival and objective response. Additionally, older age is positively associated with objective response and the majority of patients with the worst prognosis have symptom relief from treatment with chemotherapy.Keywords
This publication has 16 references indexed in Scilit:
- Prognostic factors for survival in advanced non-small-cell lung cancer: univariate and multivariate analyses including recursive partitioning and amalgamation algorithms in 1,052 patients. The European Lung Cancer Working Party.Journal of Clinical Oncology, 1995
- Symptom relief with MVP (mitomycin C, vinblastine and cisplatin) chemotherapy in advanced non-small-cell lung cancerBritish Journal of Cancer, 1995
- Future directions in the treatment of non-small cell lung cancer.1994
- Polychemotherapy in advanced non small cell lung cancer: a meta-analysisThe Lancet, 1993
- Survival determinants in extensive-stage non-small-cell lung cancer: the Southwest Oncology Group experience.Journal of Clinical Oncology, 1991
- A randomized study of cisplatin versus cisplatin plus vindesine for non-small cell lung carcinomaCancer, 1991
- A randomized trial of five cisplatin-containing treatments in patients with metastatic non-small-cell lung cancer: a Southwest Oncology Group study.Journal of Clinical Oncology, 1991
- A randomized trial in inoperable non-small-cell lung cancer: vindesine and cisplatin versus mitomycin, vindesine, and cisplatin versus etoposide and cisplatin alternating with vindesine and mitomycin.Journal of Clinical Oncology, 1991
- Randomized comparison of two combination regimens versus minimal chemotherapy in nonsmall-cell lung cancer: a Southeastern Cancer Study Group Trial.Journal of Clinical Oncology, 1990
- Chemotherapy of Advanced Non-Small-Cell Lung Cancer with Cyclophosphamide, Adriamycin, Methotrexate, and Procarbazine versus Cisplatin and Etoposide A Randomized StudyAmerican Journal of Clinical Oncology, 1988